Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today urged shareholders to vote FOR the election of all six of MindMed's highly qualified director candidates to the Board of Directors (the “Board”) in advance of the Annual Meeting of Shareholders scheduled for June 15, 2023. All proxy cards must be received by June 13, 2023 at 10:00 AM EDT in order to be counted. MindMed urges shareholders to vote online ahead of the deadline to.

MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today announced that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends shareholders vote for the election of ALL of MindMed's six highly qualified director nominees to the Board of Directors (the “Board”) at the upcoming Annual Meeting of Shareholders (“Annual Meeting”), scheduled for June 15, 2023. Previously, leading proxy advisory firm Institutional Sh.

Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will a host an Analyst Day on Tuesday, June 20th that will focus on the MM-120 program in generalized anxiety disorder (GAD).

MindMed to Host Investor Day June 2023

Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said it has been designated as a top research site for MindMed Inc's (NASDAQ:MNMD, NEO:MMED) Phase 2b study on MM-120 (lysergide D-tartrate) for General Anxiety Disorder. The company's Cedar Clinical Research (CCR), located in Draper, Utah, has emerged as the leading site for the study, having successfully enrolled and dosed 19 clinical trial participants thus far.

Numinus Wellness designated as a top research site for MindMed study

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (the “Company” or “MindMed”) today announced that leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended shareholders vote for ALL of MindMed's six highly qualified director nominees at the upcoming Annual Meeting of Shareholders (“Annual Meeting”), scheduled for June 15, 2023. In its report supporting MindMed's nominees, ISS notes the following:1 “The company's regulatory st.

Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees

VANCOUVER, BC , June 5, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder.  CCR's research clinic in Draper, Utah, is the top enrolling site for the research study – having enrolled and dosed 19 clinical trial participants for the study to date.

Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed announced today that members of the Company's management team will participate in several June investor conferences.

MindMed to Participate at Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders.

MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed Publishes Report by Leading FDA Experts Validating MindMed's MM-120 Drug Development Strategy.

MindMed Publishes Report by Leading FDA Experts Validating MindMed's MM-120 Drug Development Strategy

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data of MM-402, the Company's proprietary form of R-MDMA, in a model for autism spectrum disorder.

MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting

MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expected in late 2023.

MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed announced today that the Company's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for GAD is over 50% enrolled and dosed.

MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Speculative Buy' rating for MindMed (NASDAQ:MNMD, NEO:MMED) after the clinical-stage biotechnology company reaffirmed its budgets and clinical timelines with the release of its first quarter results. “As a clinical-stage biotechnology company, quarterly financials are not a materially impactful event,” the analysts wrote in a note to clients.

MindMed a ‘Speculative Buy' ahead of key trial data readouts, broker says

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Rob Barrow – Chief Executive Officer Schond Greenway – Chief Financial Officer Dan Karlin – Chief Medical Officer Conference Call Participants Charles Duncan – Cantor Fitzgerald Brian Abrahams – RBC Capital Markets Francois Brisebois – Oppenheimer Elemer Piros – EF Hutton Patrick Trucchio – H.C. Wainwright Operator Good afternoon, and welcome to the Mind Medicine First Quarter 2023 Financial Results and Corporate Update Conference call.

Mind Medicine (MindMed) Inc. (MNMD) Q1 2023 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed today reported its financial results for the quarter ended March 31, 2023.

MindMed Reports First Quarter 2023 Financial Results and Business Highlights

Mind Medicine (MindMed) Inc. MNMD stock fell 0.3% in premarket trades after the psychedelic medicine maker issued its letter to shareholders urging them to vote for its board of directors at its June 15 shareholder meeting rather than rival nominees from meme stock trader Jake Freeman. MindMed said its nominees “possess essential pharmaceutical industry, capital allocation and corporate governance experience” at a pivotal moment for the company.

Mind Medicine takes proxy battle to annual meeting with rival board nominees

NEW YORK--(BUSINESS WIRE)---- $MNMD--The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today sent a letter to shareholders highlighting the importance of voting at its upcoming 2023 Annual Meeting of Shareholders (the “Annual Meeting”). By voting for the Board's nominees, shareholders can support the significant progre.

MindMed Sends Letter to Shareholders Highlighting Company's Positive Momentum and Value-Enhancing Strategy

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update.

MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

Canopy Growth

The Metals Co

The search for top penny stocks to buy in April, or in any month, is certainly an intriguing one. There are thousands of small and micro-cap stocks to choose from.

3 High-Growth Penny Stocks to Consider Buying in April 2023

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate in the following investor conferences: H.C. Wainwright BioConnect Conference Format: 1x1 Investor Meetings Date: Tuesday, May 2, 2023 RBC Capital Markets Global Healthcare Conference Format: Fi.

MindMed to Participate in May Investor Conferences

NEW YORK--(BUSINESS WIRE)---- $MNMD--Presents Highly Qualified Slate of Director Nominees, Including Five Incumbent Board Members and New Independent Candidate David W. Gryska.

MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

The stock of psychedelics company Mind Medicine Inc. MNMD, +4.82% rose 4% Friday, after the company's Swiss research partners reported positive results from a Phase 2 trial of LSD as a treatment for major depressive disorder, or MDD. The trial involving 61 patients showed “rapid, durable and beneficial effects” of LSD in mitigating the symptoms of MDD, the company said in a statement.

MindMed stock jumps 4.5% after psychedelics company reports positive findings in trial of LSD as treatment for major depressive disorder

MindMed (NASDAQ:MNMD, NEO:MMED)'s shares moved higher after the biopharmaceutical company released positive topline data from its collaborators' trial evaluating lysergide (LSD) in the treatment of major depressive disorder (MDD). After spiking about 10% earlier in the day, MindMed (NASDAQ:MNMD, NEO:MMED) shares were trading up about 0.7% at US$3.12 shortly before 11am in New York.

MindMed shares spike on positive results from LSD trial

Mind Medicine (NASDAQ: MNMD ) stock is on the rise Friday after releasing positive results from a Phase 2 clinical trial. That clinical trial saw the company testing the effectiveness of treating MDD with LSD.

Why Is Mind Medicine (MNMD) Stock Up 26% Today?

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that Prof. Matthias Liechti and Dr.

News for Mind Medicine MindMed Stock (MNMD)